Tagged Articles

Januvia 202 articles

Newer users of non-insulin diabetes drugs at greater risk for pancreatic cancer

People who recently started using a type 2 diabetes medication from a newer class known as incretin mimetics had double the risk of pancreatic cancer compared to diabetics who did not take the medication. However, the risk dropped to baseline with prolonged use, according to a new study published in the journal Diabetes, Obesity and Metabolism. Researchers from Maastricht University Medical Center in the Netherlands conducted a retrospective population-based cohort study involving 182,428 patients with at least one non-insulin anti-diabetic drug (NIAD) prescription and matched them with a control group of patients who did not have diabetes. They also used a ... Read More

Four Dangerous Diabetes Drugs

Type 2 diabetes is a growing epidemic around the world with an estimated one in 10 adults predicted to be suffering from the disease by 2030, according to the International Diabetes Foundation. Diabetes increases the risk for serious health complications including heart disease, kidney disease, cancer, blindness, dementia and amputations from neuropathy. Many diabetics require medication to help control blood sugar levels. There are dozens of diabetes treatments on the market and more being developed. But these drugs come at a risk. Here are five type 2 diabetes drugs that carry dangerous side effects: Invokana/Invokamet – Known chemically as canagliflozin, Invokana ... Read More

AstraZeneca diabetes drug cocktail rejected by FDA

The Food and Drug Administration (FDA) rejected a fixed-dose drug cocktail from AstraZeneca to treat type 2 diabetes, saying not enough clinical data was provided with the drug’s application. AstraZeneca took the news hard, saying the setback would push back the drug’s launch date by a year or two, depending on whether new clinical trials would need to be conducted. The drug is a combination of two already FDA-approved drugs to treat type 2 diabetes – saxagliptin and dapagliflozin. Saxagliptin, which is sold under the brand name Onglyza, is a class of diabetes drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors, ... Read More

Advances in technology offer hope for pancreatic cancer patients

The number of new diagnoses of pancreatic cancer has nearly doubled in the past 15 years, from 29,000 in 2000 to about 50,000 today, according to the Centers for Disease Control and Prevention (CDC). There are several factors contributing to this increase, says Dr. David Kooby, director of surgical oncology at Emory St. Joseph’s Hospital. Baby boomers are aging, and the risk is higher among people in their 60s and 70s. Improvements in diagnostic technology have also helped find tumors whose spread may have confused physicians years ago. The pancreas plays an important role in the digestive tract. Dysfunction of ... Read More

Study questions sugar spike risk with diabetes drugs Byetta, Victoza

A class of drugs designed to regulate blood sugar levels in type 2 diabetics may actually trigger spikes in blood sugar levels, potentially causing more harm than good, a new study shows. The research, published in the Journal of Biological Chemistry, involved a class of drugs called GLP-1 agonists, which include the brand name drugs Byetta and Victoza. The medications work by stimulating the release of insulin by the pancreas after eating, and slowing glucose absorption in the bloodstream by reducing the speed at which the stomach empties after eating, making users feel more satisfied after a meal. However, GLP-1 ... Read More

Saxenda diet drug may increase risk of Victoza side effects

Novo Nordisk has seen success with its type 2 diabetes drug Victoza. But a different indication for the medication, which sprang from a Victoza side effect, may prove to be even more profitable for the drug company. Victoza, which contains the drug ingredient liraglutide, is a once-daily injection to treat Type 2 diabetes. It was approved by the Food and Drug Administration (FDA) in January 2010. It is in the same drug class as the diabetes medications Byetta and Januvia. One side effect from these medications is weight loss, which prompted Novo Nordisk to begin testing the drug in higher doses ... Read More

FDA warns about new risks with newer type 2 diabetes drugs

Johnson & Johnson’s rising star diabetes drug Invokana hit a snag earlier this month when the Food and Drug Administration (FDA) announced it was requiring a warning be added to the drug’s label for the risk of bone fractures and decreased bone density. The drug safety communication pointed out that a warning for bone fractures was already on the safety labels of Invokana as well as the combination drug Invokana and metformin called Invokamet. But the agency said data from new studies confirmed fractures occurred more often in patients taking Invokana compared to patients taking a placebo. The labels will ... Read More

Lawsuits claim serious injuries from type 2 diabetes drugs

A class action lawsuit filed in Canada alleges the type 2 diabetes drug Invokana can cause kidney damage so severe it could be fatal. The class action lawsuit is awaiting certification under Nova Scotia law, but attorneys say they expect no issues in getting the class action certified within the next several months. Invokana is manufactured by Johnson & Johnson unit Janssen Pharmaceuticals. It was approved by Canadian drug regulators in May 2014, about a year after the Food and Drug Administration (FDA) granted approval in the United States. It is in a new class of diabetes drugs known as ... Read More

Diabetes drugs may put users at risk for pancreatic cancer

Type 2 diabetes drugs in a class known as incretin mimetics have been linked to an increased risk of pancreatic cancer, but a new study suggests that the same risk may be present with other diabetes drugs. Incretin mimetics include the drug subclasses DPP-4 inhibitors, such as the brand name Januvia, and GLP-1 agonists, which include the brand name drugs Byetta, and Victoza. Cancer concerns with these drugs were first raised when studies on the DPP-4 inhibitor Januvia found abnormalities in the pancreases of laboratory rats. Another study found abnormal changes, including precancerous lesions, in the pancreases of eight organ ... Read More

FDA approves new warnings on newer type 2 diabetes drugs

The Food and Drug Administration (FDA) has approved updates to the safety labels of 11 similar type 2 diabetes drugs that include new warnings for severe and debilitating joint pain. The drugs are in a new class of type 2 diabetes medications known as DPP-4 inhibitors, which include the following: Glyxambi (linagliptin and empagliflozin) Januvia (sitagliptin) Janumet (sitagliptin and metformin) Janumet XR (sitagliptin and metformin extended release) Jentadueto (linagliptin and metformin) Kazano (alogliptin and metformin) Kombiglyze XR (saxagliptin and metformin extended release) Nesina (alogliptin) Onglyza (saxagliptin) Oseni (alogliptin and pioglitazone) Tradjenta (linagliptin) The condition, called arthralgia, has occurred in patients ... Read More